New Haven, CT1 Active Studies

Duchenne Muscular Dystrophy Clinical Trials in New Haven, CT

Find 1 actively recruiting duchenne muscular dystrophy clinical trials in New Haven, CT. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
2,500
Enrolling

Recruiting Duchenne Muscular Dystrophy Studies in New Haven

About Duchenne Muscular Dystrophy Clinical Trials in New Haven

Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. It is caused by mutations in the dystrophin gene. Treatment includes corticosteroids, gene therapies, and supportive care to maintain mobility and function.

There are currently 1 duchenne muscular dystrophy clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 2,500 participants. Research is being sponsored by The Duchenne Registry. Clinical trial participation is free and participants receive study-related medical care at no cost.

Duchenne Muscular Dystrophy Clinical Trials in New Haven — FAQ

Are there duchenne muscular dystrophy clinical trials in New Haven?

Yes, there are 1 duchenne muscular dystrophy clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What duchenne muscular dystrophy treatments are being tested?

The 1 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for duchenne muscular dystrophy.

Data updated August 30, 2026 from ClinicalTrials.gov